Development and biological evaluation of vesicles containing bile salt of telmisartan for the treatment of diabetic nephropathy

References

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.
   PubMed Web of Science ®Google Scholar
• Krishnan N, Velramar B, Pandiyan R, et al. Anti-pseudomonal and anti-endotoxic effects of surfactin-stabilized biogenic silver nanocubes ameliorated wound repair in streptozotocin-induced diabetic mice. Artif Cells Nanomed Biotechnol. 2017; [12 p.]. DOI:https://doi.org/10.1080/21691401.2017.1324461
   Google Scholar
• Balakumar P, Arora MK, Ganti SS, et al. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res. 2009;60:24–32.
   PubMed Web of Science ®Google Scholar
• Jahangir MA, Khan R, Sarim Imam S. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Artif Cells Nanomed Biotechnol. 2017; [13 p.]. DOI:https://doi.org/10.1080/21691401.2017.1411933
   Google Scholar
• Karnoosh-Yamchi J, Rahmati-Yamchi M, Akbarzadeh A, et al. pH sensitive insulin-loaded nanohydrogel increases the effect of oral insulin in diabetic rats. Artif Cells Nanomed Biotechnol. 2017; 45:1222–1225.
   PubMed Web of Science ®Google Scholar
• Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract. 2008;82: S75–S79.
   PubMed Web of Science ®Google Scholar
• Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl. 2000;77:S93–S98.
   PubMed Web of Science ®Google Scholar
• Gnudi L, Goldsmith D. Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep. 2010;2:18.
   PubMedGoogle Scholar
• Hahr AJ, Molitch ME. Diabetes, cardiovascular risk and nephropathy. Cardiol Clin. 2010;28:467–475.
   PubMed Web of Science ®Google Scholar
• Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res. 2011;45:575–584.
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43: 993–1002.
   PubMed Web of Science ®Google Scholar
• Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res. 2009;37: 1662–1679.
   PubMed Web of Science ®Google Scholar
• Khan AH, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens. 2011;24:816–821.
   PubMed Web of Science ®Google Scholar
• Wienen W, Richard S, Champeroux P, et al. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst. 2001;2:31–36.
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74:364–369.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: a contemporary view. Curr Diabetes Rev. 2012;8:183–190.
   PubMedGoogle Scholar
• Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging. 2010;5:403–416.
   PubMed Web of Science ®Google Scholar
• Yang L, Shao Y, Han HK. Improved pH-dependent drug release and oral exposure of telmisartan, a poorly soluble drug through the formation of drug-aminoclay complex. Int J Pharm. 2014; 471:258–263.
   PubMed Web of Science ®Google Scholar
• Sangwai M, Vavia P. Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability. Int J Pharm. 2013;453: 423–432.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Mohizea AM, Al-Jenoobi FI, et al. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. Drug Deliv. 2016;23:579–590.
   PubMed Web of Science ®Google Scholar
• Lepek P, Sawicki W, Wlodarski K, et al. Effect of amorphization method on telmisartan solubility and the tableting process. Eur J Pharm Biopharm. 2013;83:114–121.
   PubMed Web of Science ®Google Scholar
• Park J, Cho W, Cha KH, et al. Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process. Int J Pharm. 2013;441:50–55.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1–10.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068–1075.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang S, Zhang M, et al. Nanocarriers for oral drug delivery. J Drug Target. 2013;21:515–527.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Garg T, Goyal AK, et al. Role of microemuslsions in advanced drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:1177–1185.
   PubMed Web of Science ®Google Scholar
• Hallan SS, Kaur P, Kaur V, et al. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:334–349.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev. 2001;47:55–64.
   PubMed Web of Science ®Google Scholar
• Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine. 2015; 10:4797–4813.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Y, Chen J, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 2009;376:153–160.
   PubMed Web of Science ®Google Scholar
• Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6:965–974.
   PubMed Web of Science ®Google Scholar
• Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265–272.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang M, Liu C, et al. Development of liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole. Asian J Pharm Sci. 2017;12:157–164.
   Web of Science ®Google Scholar
• Niu M, Tan Y, Guan P, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014;460:119–130.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhao Y, Zhang Y, et al. Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo. Int J Nanomedicine. 2015;10:6633–6644.
   PubMed Web of Science ®Google Scholar
• Al-Mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm. 2015;485:329–340.
   PubMed Web of Science ®Google Scholar
• Guan P, Lu Y, Qi J, et al. Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. Colloids Surf B Biointerfaces. 2016;144:143–151.
   PubMed Web of Science ®Google Scholar
• Dragicevic-Curic N, Scheglmann D, Albrecht V, et al. Development of different temoporfin-loaded invasomes-novel nanocarriers of temoporfin: characterization, stability and in vitro skin penetration studies. Colloids Surf B Biointerfaces. 2009;70:198–206.
   PubMed Web of Science ®Google Scholar
• Ahad A, Raish M, Ahmad A, et al. Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharm Sci. 2018; 111:409–417.
   PubMed Web of Science ®Google Scholar
• Abdelbary AA, Abd-Elsalam WH, Al-Mahallawi AM. Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm. 2016;513:688–696.
   PubMed Web of Science ®Google Scholar
• Ahad A, Raish M, Al-Jenoobi FI, et al. Sorbitane monostearate and cholesterol based niosomes for oral delivery of telmisartan. Curr Drug Deliv. 2018;15:260–266.
   PubMed Web of Science ®Google Scholar
• Madheswaran T, Baskaran R, Yong CS, et al. Enhanced topical delivery of finasteride using glyceryl monooleate-based liquid crystalline nanoparticles stabilized by cremophor surfactants. AAPS PharmSciTech. 2014;15:44–51.
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52:313–320.
   PubMed Web of Science ®Google Scholar
• El Gamal AA, AlSaid MS, Raish M, et al. Beetroot (Beta vulgaris L.) extract ameliorates gentamicin-induced nephrotoxicity associated oxidative stress, inflammation, and apoptosis in rodent model. Mediators Inflamm. 2014;2014:1.
   Web of Science ®Google Scholar
• Towbin H. Origins of protein blotting. Methods Mol Biol. 2009;536:1–3.
   PubMedGoogle Scholar
• Hussein MM, Mahfouz MK. Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats. Biomed Pharmacother. 2016;82:685–692.
   PubMed Web of Science ®Google Scholar
• Sun J, Deng Y, Wang S, et al. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv. 2010;17:164–170.
   PubMed Web of Science ®Google Scholar
• Biruss B, Dietl R, Valenta C. The influence of selected steroid hormones on the physicochemical behaviour of DPPC liposomes. Chem Phys Lipids. 2007;148:84–90.
   PubMed Web of Science ®Google Scholar
• Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2016;23:1847–1867.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, et al. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine. 2010;5:287–306.
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhou R, Liu L, et al. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine. 2013;8:1921–1933.
   PubMed Web of Science ®Google Scholar
• Shukla A, Khatri K, Gupta PN, et al. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 2008;11:59–66.
   PubMed Web of Science ®Google Scholar
• Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441:693–700.
   PubMed Web of Science ®Google Scholar